EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

A B M Kamrul-Hasan iD, Arnav Kalra iD, Nitin Kapoor iD, Deep Dutta iD, Kunal Mahajan iD, Robin Maskey iD, Syed Abbas Raza iD

Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)

DOI: 10.1002/edm2.70307 ↗

At a glance

Übersichtsarbeit in Endocrinology, Diabetes & Metabolism, published online on 2026-08-11. Written by A B M Kamrul-Hasan and 6 co-authors. Institution: Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh. Major MEDLINE topics: Obesity, Anti-Obesity Agents. 64 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Conventional single‐agent drugs yield modest, plateauing weight loss and often lead to weight regain. Combination pharmacotherapy is a logical next step to target complementary pathways of weight control while reducing toxicity and treatment burden. This review synthesises mechanisms and clinical evidence for fixed‐dose combinations, multi‐agonist peptides, add‐on regimens and multimodal strategies integrating pharmacotherapy with procedures.

Methods

We conducted a narrative review of clinical trials and observational studies on approved and emerging obesity pharmacotherapy combinations, focusing on mechanistic complementarity, efficacy, safety and practical implementation. Agents were mapped to three domains of energy homeostasis—homeostatic appetite regulation, hedonic‐reward circuitry and peripheral metabolic effector pathways—to inform interpretation of combination strategies.

Results

Fixed‐dose combinations such as phentermine‐topiramate and naltrexone‐bupropion yield greater weight loss than their individual components but also carry gastrointestinal, cardiovascular and neuropsychiatric risks. Multi‐agonist peptides integrating GLP‐1, GIP, glucagon, or amylin deliver double‐digit weight loss and improve glycemic and cardiometabolic profiles, but increase the risk of gastrointestinal adverse events, requiring close monitoring. Add‐on regimens that combine GLP‐1 agonists with approved obesity medications or SGLT‐2 inhibitors, and multimodal strategies that pair drugs with bariatric or endoscopic procedures, generally show additive rather than truly synergistic effects on weight loss.

Conclusions

Available data suggest that combination pharmacotherapy can extend current approaches to precision obesity care, generally providing additive benefits alongside increased regimen complexity, costs and adverse‐event risks. Thoughtful, phenotype‐guided selection and comparative studies versus potent monotherapies, enriched by multi‐omics and behavioural insights, may clarify which patients benefit most and sustainably from these strategies.

Subjects

MeSH terms (MEDLINE)

ObesityAnti-Obesity AgentsHumansDrug Therapy, CombinationWeight Loss

Author keywords

GLP‐1 receptor agonistscombination pharmacotherapyfixed‐dose combinationsmulti‐agonist peptidesobesity management medicationsprecision obesity medicine

Substances

Anti-Obesity Agents

Authors and institutions

  • Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh.
  • Department of Endocrinology & Metabolism, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India.
  • Non-Communicable Disease Unit, Melbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, Australia.
  • Department of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi, India.
  • Department of Cardiology, Himachal Heart Institute, Mandi, Himachal Pradesh, India.

ORCID profiles: A B M Kamrul-Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza

Cite

APA

Kamrul-Hasan, A. B. M., Kalra, A., Kapoor, N., Dutta, D., Mahajan, K., Maskey, R., & Raza, S. A. (2026). Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70307

Vancouver

Kamrul-Hasan ABM, Kalra A, Kapoor N, Dutta D, Mahajan K, Maskey R, et al. Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70307

BibTeX
@article{KamrulHasan2026,
  author = {Kamrul-Hasan, A B M and Kalra, Arnav and Kapoor, Nitin and Dutta, Deep and Mahajan, Kunal and Maskey, Robin and Raza, Syed Abbas},
  title = {Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  volume = {9},
  number = {5},
  doi = {10.1002/edm2.70307}
}
Start for free →